{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-200629","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.089726+00:00","generated_at":"2026-05-31T09:21:52.119618+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tectonic reports Q2 net loss $12.7M; cash $185.1M; TX45 Phase 2 trial open","bullets":["Net loss of $12.7M for Q2 2024 vs $10.5M in Q2 2023; R&D expenses $7.1M.","Cash and cash equivalents $185.1M as of June 30, providing runway into mid-2027.","TX45 Phase 2 APEX trial for PH-HFpEF open for screening; first dosing expected Sept 2024.","Closed reverse merger with AVROBIO in June 2024, with concurrent $130.7M private placement.","Appointed Dan Lochner as CFO in June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-200629","json":"https://secwatch.observer/filing/0001193125-24-200629.json","markdown":"https://secwatch.observer/filing/0001193125-24-200629.md","text":"https://secwatch.observer/filing/0001193125-24-200629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524200629/0001193125-24-200629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524200629/d838115d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:21:52.119618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}